Patents by Inventor Franz Birke

Franz Birke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7723360
    Abstract: A compound of general formula 1a wherein R1, R5, R6, A, B, Y, i, j and m are defined as in the description and claims. It is another object of the present invention to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 28, 2005
    Date of Patent: May 25, 2010
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Ralf Anderskewitz, Domnic Martyres, Franz Birke, Thierry Bouyssou
  • Patent number: 7544806
    Abstract: Accordingly, one object of the present invention are novel piperidine-substituted indoles- or heteroderivatives thereof of the formula 1: wherein R1, R5, R6, A, B, D-E, X-W-V, Y, i, j, n and m are defined as below. Another object of the present invention is to provide agonists or antagonists of CCR-3, or pharmaceutically acceptable salts thereof, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 16, 2004
    Date of Patent: June 9, 2009
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Ralf Anderskewitz, Franz Birke, Thierry Bouyssou, Horst Dollinger, Domnic Martyres, Pascale Pouzet
  • Publication number: 20080171749
    Abstract: The invention relates to the use of 1-phenyl-1,2-diaminoethane derivatives of formula (I) wherein the groups A, R1, R2 and Ra through Rj have the meanings given in the claims and specification, for the preparation of a medicament for the treatment and/or prevention of a disease, wherein the activity of a CCR3 receptor is involved and to novel compounds of formula (I), wherein A represents —CH2CH2— or —C(?O)—NH—.
    Type: Application
    Filed: February 27, 2008
    Publication date: July 17, 2008
    Inventors: Horst DOLLINGER, Franz Birke, Pascale Arielle Jene-Josee Pouzet, Enzo Cereda, Monica Quai
  • Patent number: 7214703
    Abstract: Disclosed are compounds of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, wherein the groups Ar1, Ar2, A, R1, R2, R3, E1, E2, X and n are as defined in the description and claims, which are effective modulators of chemokine activity.
    Type: Grant
    Filed: February 4, 2004
    Date of Patent: May 8, 2007
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Ralf Anderskewitz, Horst Dollinger, Claudia Heine, Pascale Arielle Jane-Josee Pouzet, Thierry Bouyssou, Franz Birke
  • Patent number: 7157471
    Abstract: A compound of general formula 1 wherein R1, R5, R6, A, B, Y, i, j and m are defined as in the description and claims. It is another object of the present invention to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 23, 2004
    Date of Patent: January 2, 2007
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Ralf Anderskewitz, Franz Birke, Thierry Bouyssou, Horst Dollinger, Domnic Martyres, Pascale Pouzet
  • Publication number: 20060030590
    Abstract: A compound of general formula 1a wherein R1, R5, R6, A, B, Y, i, j and m are defined as in the description and claims. It is another object of the present invention to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 28, 2005
    Publication date: February 9, 2006
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Ralf Anderskewitz, Domnic Martyres, Franz Birke, Thierry Bouyssou
  • Patent number: 6921752
    Abstract: The invention relates to the use of LTB4 antagonists for preparing a pharmaceutical composition for the treatment or prevention of respiratory diseases in companion and domesticated animals.
    Type: Grant
    Filed: March 24, 2003
    Date of Patent: July 26, 2005
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Franz Birke, Kandace Matzek
  • Publication number: 20050153979
    Abstract: Accordingly, one object of the present invention are novel piperidine-substituted indoles- or heteroderivatives thereof of the formula 1: wherein R1, R5, R6, A, B, D-E, X—W—V, Y, i, j, n and m are defined as below. Another object of the present invention is to provide agonists or antagonists of CCR-3, or pharmaceutically acceptable salts thereof, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 16, 2004
    Publication date: July 14, 2005
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Ralf Anderskewitz, Franz Birke, Thierry Bouyssou, Horst Dollinger, Domnic Martyres, Pascale Pouzet
  • Publication number: 20050124659
    Abstract: A compound of general formula 1 wherein R1, R5, R6, A, B, Y, i, j and m are defined as in the description and claims. It is another object of the present invention to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 23, 2004
    Publication date: June 9, 2005
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Ralf Anderskewitz, Franz Birke, Thierry Bouyssou, Horst Dollinger, Dominic Martyres, Pascale Pouzet
  • Publication number: 20050027122
    Abstract: Disclosed are compounds of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, wherein the groups Ar1, Ar2, A, R1, R2, R3, E1, E2, X and n are as defined in the description and claims, which are effective modulators of chemokine activity.
    Type: Application
    Filed: February 4, 2004
    Publication date: February 3, 2005
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Ralf Anderskewitz, Horst Dollinger, Claudia Heine, Pascale Pouzet, Thierry Bouyssou, Franz Birke
  • Publication number: 20050014782
    Abstract: Use of a compound of general formula 1 for manufacturing a medicament to provide agonists or antagonists of CCR-3, or pharmaceutically acceptable salts thereof, in particular compounds of formula 1: wherein R1, R5, R6, A, B, X, W, Z, i, j, k, l and m are defined as in the description and claims. It is another object of the present invention to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 8, 2004
    Publication date: January 20, 2005
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Ralf Anderskewitz, Franz Birke, Thierry Bouyssou, Horst Dollinger, Domnic Martyres, Pascale Pouzet
  • Publication number: 20040116516
    Abstract: The invention relates to a pharmaceutical formulation comprising a LTB4 antagonist having a hydroxy and a benzamidine group or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, in particular a compound of formula (I) 1
    Type: Application
    Filed: November 21, 2003
    Publication date: June 17, 2004
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Franz Birke, Hans Michael Jennewein
  • Publication number: 20040063779
    Abstract: The invention relates to the use of 1-phenyl-1,2-diaminoethane derivatives of formula (I) 1
    Type: Application
    Filed: July 7, 2003
    Publication date: April 1, 2004
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Horst Dollinger, Franz Birke, Pascale Arielle Jane-Josee Pouzet, Enzo Cereda, Monica Quai
  • Publication number: 20030225004
    Abstract: The invention relates to the use of LTB4 antagonists for preparing a pharmaceutical composition for the treatment or prevention of respiratory diseases in companion and domesticated animals.
    Type: Application
    Filed: March 24, 2003
    Publication date: December 4, 2003
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Franz Birke, Kandace Matzek
  • Publication number: 20030181518
    Abstract: A method of treating or preventing cystic fibrosis in a patient in need of such treatment, the method comprising administering to the patient a therapeutically effective amount of an LTB4 antagonist of formula (I) 1
    Type: Application
    Filed: April 15, 2003
    Publication date: September 25, 2003
    Applicant: Boehringer Ingelheim Pharma KG
    Inventors: Ralf Anderskewitz, Christopher J. Montague Meade, Franz Birke, Hans Michael Jennewein, Birgit Jung
  • Publication number: 20030130232
    Abstract: Compounds of the formula 1
    Type: Application
    Filed: September 23, 2002
    Publication date: July 10, 2003
    Applicant: Boehringer Ingelheim KG
    Inventors: Ralf Anderskewitz, Kurt Schromm, Ernst-Otto Renth, Frank Himmelsbach, Franz Birke, Armin Fugner
  • Patent number: 6576669
    Abstract: Medicaments and pharmaceutical kits comprising an LTB4 antagonist of formula (I) a tautomer thereof or a pharmaceutically acceptable salt thereof, and methods of treating or preventing cystic fibrosis, diseases caused by increased expression of mucin genes in the bronchial or gastrointestinal epithelium, or hyperplasia of goblet cells induced by toxins of products of pathogenic bacteria in a patient in need of such treatment, the method comprising administering to the patient a therapeutically effective amount of an LTB4 antagonist of formula (I).
    Type: Grant
    Filed: January 16, 2002
    Date of Patent: June 10, 2003
    Assignee: Boehringer Ingelheim Pharma KG
    Inventors: Ralf Anderskewitz, Christopher J. Montague Meade, Franz Birke, Hans Michael Jennewein, Birgit Jung
  • Patent number: 6528491
    Abstract: The present invention relates to new pyranoside derivatives of general formula I, processes for preparing them as well as their use as medicaments:
    Type: Grant
    Filed: October 23, 2001
    Date of Patent: March 4, 2003
    Assignee: Boehringer Ingelheim Pharma KG
    Inventors: Ralf Anderskewitz, Kurt Schromm, Franz Birke, Hans Michael Jennewein
  • Patent number: 6489359
    Abstract: The present invention relates to new sulphoxybenzamides of general formula I, processes for preparing them as well as their use as medicaments.
    Type: Grant
    Filed: October 23, 2001
    Date of Patent: December 3, 2002
    Assignee: Boehringer Ingelheim Pharma KG
    Inventors: Ralf Anderskewitz, Kurt Schromm, Franz Birke, Hans Michael Jennewein
  • Patent number: 6489365
    Abstract: Compounds of the formula which is explained more fully in the specification, may be prepared by conventional methods and used therapeutically in conventional galenic preparations.
    Type: Grant
    Filed: January 18, 2000
    Date of Patent: December 3, 2002
    Assignee: Boehringer Ingelheim KG
    Inventors: Ralf Anderskewitz, Kurt Schromm, Ernst-Otto Renth, Frank Himmelsbach, Franz Birke, Armin Fugner